Targets › RSVG
1 program from 1 company in 1 trial: 1 Phase 4; Vaccines; next expected readout Feb 2027.
Open in Phaseline: the race on RSVG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Duke University | Nirsevimab Fusion glycoprotein F0 inhibitor | RSVG | Phase 4 | Fever | Feb 2027 |
Fever (1)
other (1)
Duke University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.